DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
- First Posted Date
- 2021-01-13
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 180
- Registration Number
- NCT04707248
- Locations
- 🇺🇸
Florida Cancer Lake Mary, Lake Mary, Florida, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Oklahoma University, Oklahoma City, Oklahoma, United States
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
- Conditions
- Interventions
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 490
- Registration Number
- NCT04704934
- Locations
- 🇦🇷
Instituto Medico Especializado Alexander Fleming, Colegiales, Caba, Argentina
🇦🇷IONC Instituto Oncologico de Cordoba - Fundacion Richardet Longo, Nueva Cordoba, Cordoba, Argentina
🇦🇷Exelsus, San Miguel De Tucumán, Tucumán, Argentina
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
- Conditions
- Interventions
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 155
- Registration Number
- NCT04703192
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
🇺🇸Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY, Palo Alto, California, United States
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 280
- Registration Number
- NCT04676477
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
- Conditions
- Interventions
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 590
- Registration Number
- NCT04656652
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇵🇱Szpital Specjalistyczny w Prabutach Sp. z o.o., Prabuty, Poland
Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 152
- Registration Number
- NCT04644237
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇦University Health Network, Toronto, Canada
🇦🇺Princess Alexandra Hospital, Woolloongabba, Australia
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 30
- Registration Number
- NCT04635111
- Locations
- 🇺🇸
Kelsey Seybold Clinic - Pearland, Houston, Texas, United States
🇺🇸Kamalesh K Sankhala MD INC, Santa Monica, California, United States
🇺🇸OSU - James Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Conditions
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1600
- Registration Number
- NCT04622319
- Locations
- 🇺🇸
MedStar Franklin Square Cancer Center at Loch Raven Campus, Baltimore, Maryland, United States
🇺🇸Houston Methodist Sugarland, Sugar Land, Texas, United States
🇺🇸MultiCare Cancer Center Puyallup, Puyallup, Washington, United States
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 277
- Registration Number
- NCT04619004
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital (MGH) - Hematology/Oncology, Boston, Massachusetts, United States
🇨🇳University of Electronic Science & Technology of China (UESTC) - Sichuan Cancer Hospital & Institute (Sichuan Provincial Tumor Hospital, Chengdu, China
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT04526704
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇳🇱Leiden University Medical Center (LUMC), Leiden, Netherlands
🇺🇸Washington University, Saint Louis, Missouri, United States